Taking this into account, a new algorithm called EUREKA was developed to stratify the probability of obstetric complications in APS patients with different aPL titers and evaluate the effectiveness of the therapy based on the aPL profile [10]. The gene discussed is FASLG; the disease is autoimmune polyendocrinopathy.